In 2015, a pilot trial of combined vemurafenib and panitumumab in BRAF-mutant mCRC patients post chemotherapy reported that the treatment limited tumour progression and resulted in modest clinical activity [98]. This evidence concerns the gene BRAF and neoplasm.